Clinical Research Directory

Inclusion Criteria: * \- Patients with histologically verified breast cancer and neoadjuvant or adjuvant treatment with a taxane derivate (e.g., Paclitaxel, Docetaxel): This group was chosen due to relatively high risk of neuropathy due to this special therapeutic agent 1,9. * Cumulative dose of at least 3 cycles * Interval of 2 weeks since the last chemotherapeutic cycle in order to prevent false worsenings due to delayed neurotoxic effects * Life expectancy of at least 3 months * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 (that is, the capability to walk and to spend less than 50% of waking hours sitting or lying) * Ability to walk (with or without aids) * European Organisation for Research and Treatment of Cancer (EORTC) common toxicity criteria (CTC) peripheral sensory neuropathy grade 1 or 2 * Intensity of paresthesias of \> 3/10 on the Visual Analog Scale (VAS) Exclusion Criteria: * \- Prevalent neuropathy of different etiology * Serious central-neurological or psychiatric disorder that would interfer with a proper order of the study, according to the judgement of the investigators * Epilepsy * Minors or persons unable to give informed consent * Current neurotoxic medication * Implanted pacemakers or defibrillators * Pregnancy * Wounds in the area to be treated, acute local or systemic infection * Peripheral arterial occlusive disease \> grade 2